{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:47:49Z","timestamp":1782409669526,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004206","name":"The University of Osaka","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004206","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Recent studies have demonstrated the utility of fibroblast activation protein inhibitor (FAPI)-positron emission tomography (PET) for cancer diagnosis. We investigated the diagnostic capability of [\n                      <jats:sup>18<\/jats:sup>\n                      F]FAPI-74 PET in patients with lung cancer eligible for surgery.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This study included 30 patients (June 2022 to February 2024) who underwent [\n                      <jats:sup>18<\/jats:sup>\n                      F]FAPI-74 PET followed by lung resection at our institution and were pathologically diagnosed with primary lung cancer. The histological types included 24 adenocarcinomas, four squamous cell carcinomas, and two small cell carcinomas or combined small cell carcinomas and adenocarcinomas. Fibroblast activation protein (FAP) expression was evaluated in surgically resected specimens of primary tumors and lymph nodes using immunohistochemical staining.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      All 30 primary lung lesions showed uptake on [\n                      <jats:sup>18<\/jats:sup>\n                      F]FAPI-74 PET (median maximum standardized uptake value [SUVmax]\u2009=\u20094.8; range: 1.2\u201315.5). A positive correlation was observed between the SUVmax of [\n                      <jats:sup>18<\/jats:sup>\n                      F]FAPI-74 PET and FAP expression by immunohistochemical staining (FAP-positive area,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0083; H-score,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0076). The sensitivity and specificity of [\n                      <jats:sup>18<\/jats:sup>\n                      F]FAPI-74 PET for the diagnosis of lymph node metastases were 75.0% and 88.5%, respectively. In all six cases of significant [\n                      <jats:sup>18<\/jats:sup>\n                      F]FAPI-74 uptake in lymph nodes, FAP expression was confirmed in the lymph node tissue by immunohistochemical staining. Three patients demonstrated lymph node uptake on [\n                      <jats:sup>18<\/jats:sup>\n                      F]FAPI-74 PET due to preoperative chemoradiation therapy or reactive lymph node enlargement\/uptake without any malignant findings.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      In resectable early-stage lung cancer, [\n                      <jats:sup>18<\/jats:sup>\n                      F]FAPI-74 PET correlated with histological FAP expression and proved useful for detecting lymph node metastases, although caution is warranted when interpreting the findings after preoperative therapy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10147-026-03047-6","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:24:15Z","timestamp":1780410255000},"page":"1336-1344","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fibroblast activation protein inhibitor-PET\/CT in lung cancer: a prospective single-center study with histopathological correlation of fibroblast activation protein expression"],"prefix":"10.1007","volume":"31","author":[{"given":"Takashi","family":"Hiroshima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4504-232X","authenticated-orcid":false,"given":"Toru","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Watabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiisa","family":"Omura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kanou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Ose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuaki","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik L.","family":"Giesel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Morii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Shintani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"3047_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"3047_CR2","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3390\/cancers15020335","volume":"15","author":"Y Shintani","year":"2023","unstructured":"Shintani Y, Kimura T, Funaki S et al (2023) Therapeutic targeting of cancer-associated fibroblasts in the non-small cell lung cancer tumor microenvironment. Cancers (Basel) 15:335. https:\/\/doi.org\/10.3390\/cancers15020335","journal-title":"Cancers (Basel)"},{"key":"3047_CR3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s40364-020-00245-w","volume":"8","author":"C Han","year":"2020","unstructured":"Han C, Liu T, Yin R (2020) Biomarkers for cancer-associated fibroblasts. Biomark Res 8:64. https:\/\/doi.org\/10.1186\/s40364-020-00245-w","journal-title":"Biomark Res"},{"key":"3047_CR4","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1055\/s-2008-1076745","volume":"29","author":"LT Tanoue","year":"2008","unstructured":"Tanoue LT (2008) Staging of non-small cell lung cancer. Semin Respir Crit Care Med 29:248\u2013260. https:\/\/doi.org\/10.1055\/s-2008-1076745","journal-title":"Semin Respir Crit Care Med"},{"key":"3047_CR5","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00408-013-9500-6","volume":"191","author":"YT Sim","year":"2013","unstructured":"Sim YT, Goh YG, Dempsey MF et al (2013) PET-CT evaluation of solitary pulmonary nodules: correlation with maximum standardized uptake value and pathology. Lung 191:625\u2013632. https:\/\/doi.org\/10.1007\/s00408-013-9500-6","journal-title":"Lung"},{"key":"3047_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009519.pub2","author":"M Schmidt-Hansen","year":"2014","unstructured":"Schmidt-Hansen M, Baldwin DR, Hasler E et al (2014) PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD009519.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"3047_CR7","doi-asserted-by":"publisher","first-page":"109168","DOI":"10.1016\/j.biopha.2019.109168","volume":"117","author":"WT Rahman","year":"2019","unstructured":"Rahman WT, Wale DJ, Viglianti BL et al (2019) The impact of infection and inflammation in oncologic 18F-FDG PET\/CT imaging. Biomed Pharmacother 117:109168. https:\/\/doi.org\/10.1016\/j.biopha.2019.109168","journal-title":"Biomed Pharmacother"},{"key":"3047_CR8","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1007\/s00259-020-04769-z","volume":"47","author":"H Chen","year":"2020","unstructured":"Chen H, Pang Y, Wu J et al (2020) Comparison of [68Ga]. Eur J Nucl Med Mol Imaging. DOTA-FAPI, Ga 47:1820\u20131832. https:\/\/doi.org\/10.1007\/s00259-020-04769-z","journal-title":"DOTA-FAPI, Ga"},{"key":"3047_CR9","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.2967\/jnumed.123.265486","volume":"64","author":"T Watabe","year":"2023","unstructured":"Watabe T, Naka S, Tatsumi M et al (2023) Initial evaluation of [18F]FAPI-74 PET for various histopathologically confirmed cancers and benign lesions. J Nucl Med 64:1225\u20131231. https:\/\/doi.org\/10.2967\/jnumed.123.265486","journal-title":"J Nucl Med"},{"key":"3047_CR10","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E et al (2012) Fiji: an open-source platform for biological-image analysis. Nat Methods 9:676\u2013682. https:\/\/doi.org\/10.1038\/nmeth.2019","journal-title":"Nat Methods"},{"key":"3047_CR11","doi-asserted-by":"publisher","first-page":"155380","DOI":"10.1016\/j.prp.2024.155380","volume":"259","author":"T Kimura","year":"2024","unstructured":"Kimura T, Watabe T, Matsui T et al (2024) Expression of fibroblast activation protein in intrathoracic solitary fibrous tumor. Pathol Res Pract 259:155380. https:\/\/doi.org\/10.1016\/j.prp.2024.155380","journal-title":"Pathol Res Pract"},{"key":"3047_CR12","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1158\/2159-8290.CD-21-1714","volume":"12","author":"JA Grout","year":"2022","unstructured":"Grout JA, Sirven P, Leader AM et al (2022) Spatial positioning and matrix programs of cancer-associated fibroblasts promote T-cell exclusion in human lung tumors. Cancer Discov 12:2606\u20132625. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1714","journal-title":"Cancer Discov"},{"key":"3047_CR13","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s00259-021-05638-z","volume":"49","author":"Y Wei","year":"2022","unstructured":"Wei Y, Cheng K, Fu Z et al (2022) [18F]AlF-NOTA-FAPI-04 PET\/CT uptake in metastatic lesions on PET\/CT imaging might distinguish different pathological types of lung cancer. Eur J Nucl Med Mol Imaging 49:1671\u20131681. https:\/\/doi.org\/10.1007\/s00259-021-05638-z","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3047_CR14","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.3390\/ph17111468","volume":"17","author":"L Zanoni","year":"2024","unstructured":"Zanoni L, Fortunati E, Cuzzani G et al (2024) [68Ga]Ga-FAPI-46 PET\/CT for staging suspected\/confirmed lung cancer: results on the surgical cohort within a monocentric prospective trial. Pharmaceuticals (Basel) 17:1468. https:\/\/doi.org\/10.3390\/ph17111468","journal-title":"Pharmaceuticals (Basel)"},{"key":"3047_CR15","doi-asserted-by":"publisher","first-page":"924223","DOI":"10.3389\/fonc.2022.924223","volume":"12","author":"J Wu","year":"2022","unstructured":"Wu J, Deng H, Zhong H et al (2022) Comparison of 68Ga-FAPI and 18F-FDG PET\/CT in the evaluation of patients with newly diagnosed non-small cell lung cancer. Front Oncol 12:924223. https:\/\/doi.org\/10.3389\/fonc.2022.924223","journal-title":"Front Oncol"},{"key":"3047_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40644-024-00701-y","volume":"24","author":"Y Li","year":"2024","unstructured":"Li Y, Zhang Y, Guo Z et al (2024) [18F]FAPI adds value to [18F]FDG PET\/CT for diagnosing lymph node metastases in stage I-IIIA non-small cell lung cancer: a prospective study. Cancer Imaging 24:68. https:\/\/doi.org\/10.1186\/s40644-024-00701-y","journal-title":"Cancer Imaging"},{"key":"3047_CR17","doi-asserted-by":"publisher","first-page":"20220463","DOI":"10.1259\/bjr.20220463","volume":"96","author":"M Hotta","year":"2023","unstructured":"Hotta M, Rieger AC, Jafarvand MG et al (2023) Non-oncologic incidental uptake on FAPI PET\/CT imaging. Br J Radiol 96:20220463. https:\/\/doi.org\/10.1259\/bjr.20220463","journal-title":"Br J Radiol"},{"key":"3047_CR18","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.matbio.2017.12.003","volume":"67","author":"D Avery","year":"2018","unstructured":"Avery D, Govindaraju P, Jacob M et al (2018) Extracellular matrix directs phenotypic heterogeneity of activated fibroblasts. Matrix Biol 67:90\u2013106. https:\/\/doi.org\/10.1016\/j.matbio.2017.12.003","journal-title":"Matrix Biol"},{"key":"3047_CR19","doi-asserted-by":"publisher","first-page":"908","DOI":"10.3390\/cancers15030908","volume":"15","author":"S Taralli","year":"2023","unstructured":"Taralli S, Lorusso M, Perrone E et al (2023) PET\/CT with fibroblast activation protein inhibitors in breast cancer: diagnostic and theranostic application\u2014a literature review. Cancers (Basel) 15:908. https:\/\/doi.org\/10.3390\/cancers15030908","journal-title":"Cancers (Basel)"},{"key":"3047_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40001-023-01494-9","volume":"29","author":"Y Sun","year":"2024","unstructured":"Sun Y, Sun Y, Li Z et al (2024) 18F-FAPI PET\/CT performs better in evaluating mediastinal and hilar lymph nodes in patients with lung cancer: comparison with 18F-FDG PET\/CT. Eur J Med Res 29:9. https:\/\/doi.org\/10.1186\/s40001-023-01494-9","journal-title":"Eur J Med Res"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03047-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03047-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03047-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:19:23Z","timestamp":1782407963000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03047-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["3047"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03047-6","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"19 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Frederik Giesel is an advisor at ABX, Telix, SOFIE Biosciences, and \u03b1-Fusion and holds shares in the consultancy group iTheranostic. The other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was reviewed and approved by the Institutional Review Board of Osaka University Hospital (approval number: 21472\u20134) and conducted in accordance with the ethical standards of the Declaration of Helsinki (2024). Written informed consent was obtained from all patients before their inclusion in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}